Navigation Links
Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
Date:11/8/2011

imary efficacy endpoint was in-stent late lumen loss. Safety was assessed by incidence of major adverse cardiac events (MACE) and presence of strut coverage with tissue within the treated artery at each time point. William Wijns, M.D., Cardiovascular Center, Aalst, Belgium and John Ormiston, M.D., Mercy Angiography Unit, Auckland, NZ are co-principal investigators for this trial.

The DESSOLVE II CE Mark trial is a multi-center study of patients with documented stable or unstable angina pectoris. The primary endpoint is superiority of the MiStent DES in minimizing in-stent late lumen loss at nine months, compared to Medtronic's Endeavor® Sprint DES, as measured by the angiography core laboratory in de novo coronary lesions in vessels ranging in diameter from 2.5 to 3.5 mm and amenable to treatment with a maximum 30 mm length stent.  The DESSOLVE II study completed enrollment of 183 patients in July 2011.

About the MiStent DES

The MiStent Sirolimus-Eluting Coronary Stent System is designed to optimize healing in patients with coronary artery disease. Micell's rapid-absorbing drug/polymer coating is intended to precisely and consistently control drug elution and polymer exposure duration to reduce the safety risks associated with current commercially available drug-eluting stent technologies.

The MiStent DES innovative stent system includes a proprietary stent coating that contains crystalline drug (sirolimus) and an absorbable polymer. As the polymer softens and disperses from the stent into the adjacent tissue, the coating provides controlled and sustained release of therapeutic levels of drug within the surrounding tissue. Results of animal studies have determined that the drug/polymer coating is cleared from the stent in 45 to 60 days leaving a bare metal stent and the polymer is completely absorbed into the surrounding tissue in 90 days to promote long-term patency and compatibility with the artery.'/>"/>

SOURCE Micell Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micell Technologies Announces Presentation of Clinical Data at TCT 2011
2. Micell Technologies Completes Enrollment in DESSOLVE II Study of the MiStent® Drug-Eluting Coronary Stent
3. Micell Technologies Announces Reduced Clinical Trial Sample Size for MiStent® Drug-Eluting Coronary Stent Based on Early Clinical Data
4. Micell Technologies Enrolls First Patient in CE Mark DESSOLVE II Study of MiStent™ Drug-Eluting Coronary Stent (DES)
5. BioMarCare Technologies Ltd. Granted Access to Archived Samples in the Hadassah Medical Center
6. Medisafe 1 Technologies Pre-pays Additional 2 Convertible Promissory Notes Due in Full to Avoid Dilution to Shareholders
7. Filtrona Porous Technologies to Introduce New Hydrophilic Foam Products for Advanced Wound Care at the MEDICA / COMPAMED Trade Fair
8. China Medical Technologies to Announce Results for the Second Fiscal Quarter Ended September 30, 2011 on November 18, 2011
9. AquaLiv Technologies Subsidiary AquaLiv, Inc. Discusses Registration In Kenya Concerning Its HIV/AIDS Treatment
10. The Future of GPCRs in Drug Discovery: Novel technologies, leading companies, and opportunities for target expansion
11. Connectyx Technologies to Host Teleconference on Third Quarter Financial Results on Tuesday November 15, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Tobramycin Market, 2010-2019" ... traditional antibiotic whose eye drop and ointment are the ... infection or inflammation caused by eye infection. Currently, dozens ... able to produce tobramycin, among which the Top 5 ...
(Date:8/28/2015)... 2015 Research and ... of the "Investigation Report on China,s Latanoprost ... Developed by Pharmacia & Upjohn in 1995, ... effectively reduces intraocular pressure. As the first pressure- ... trade name of Xalatan) entered China ...
(Date:8/28/2015)... Aug. 28, 2015  Perrigo Company plc ("Perrigo") (NYSE: ... completed the acquisition of leading OTC brands from GSK ... The transaction is a clear demonstration of Perrigo,s unique ... European distribution network spanning 36 countries.  ... commented, "We are excited to complete this transaction, ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Latanoprost Market Investigation Report 2015-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
... Md., Jan. 31, 2011 Vanda Pharmaceuticals Inc. (Vanda) ... on the development and commercialization of products for central ... a universal shelf registration statement on Form S-3 with ... effective by the SEC, the shelf registration statement will ...
... Technologies, Inc. (the "Company") (Nasdaq: CMED ), ... announced that it will report its unaudited financial results ... before the U.S. market opens on February 18, 2011. ... 2011. The Company,s senior management will ...
Cached Medicine Technology:Vanda Pharmaceuticals Files Shelf Registration Statement 2Vanda Pharmaceuticals Files Shelf Registration Statement 3Vanda Pharmaceuticals Files Shelf Registration Statement 4China Medical Technologies to Announce Results for the Third Fiscal Quarter Ended December 31, 2010 on February 18, 2011 2
(Date:8/28/2015)... ... 2015 , ... Approximately 2,000 United Methodists are expected to ... children, a thank you to the many creative and generous ways in which ... Methodist initiative to end malaria deaths. , The Columbus Zoo and Aquarium event, ...
(Date:8/28/2015)... ... August 28, 2015 , ... An article published August 19th by ... has gone through to open a pizzeria in Westchester. Mr. LaRocco was aware from ... several months, but the current process, having already gone on for over a year, ...
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time is nearing for the ... USPI Tenet Health. , The American Heart Association hosts their well-known Heart Walk to ... that together, a difference can be made. Walkers can participate in the cause and ...
(Date:8/28/2015)... ... ... As reported by Medical Daily on August 22 , Cellfina, a ... for two years, the longest of any cellulite reduction system currently on the market. ... effective solution for their cellulite, according to Dr. Robert Weiss, director of the premier ...
(Date:8/28/2015)... ... August 28, 2015 , ... On May 30th, 2015, ... as sponsor of the “Music With A Mission” benefit concert in Mendon, IL. Held ... was to raise money to support music education programs in the underfunded local school ...
Breaking Medicine News(10 mins):Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2
... Oct. 31 /Xinhua-PRNewswire-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. ... a U.S. pharmaceutical company with its principal ... granted leave by the American,Arbitration Association ("AAA") ... defamation and breach of contract in a ...
... to be anti-inflammatory in several animal injury models. Recent ... and liver against lethal doses of endotoxin in rat ... transplantation. The influence of dietary glycine on oxidant-induced or ... article to be published on October 21, 2008 in ...
... International Osteoporosis Foundation (IOF) has backed the National Osteoporosis ... on the prevention and treatment of osteoporosis. ... National Societies said "we support any initiative that is ... in this instance we do not believe this is ...
... latest advances in,autism research, treatment and therapy will ... Lauderdale. The comprehensive four-day,conference, hosted by the National ... for November 13 through 16 at the Hyatt ... The conference will feature keynote speaker U.S. ...
... Wolters Kluwer, a,market leading global information services and ... of Robert Becker to the,position of President and ... Becker is currently CEO of Wolters Kluwer Law ... CEO of Wolters Kluwer Law &,Business (U.S.)., ...
... 31 SCOLR Pharma, Inc.,(Amex: DDD ) today ... Friday, November 7, 2008, at 8:30 a.m. Eastern. Daniel ... the conference call at 11:30,a.m. Eastern, to discuss the ... interested parties may participate in the,conference call by dialing ...
Cached Medicine News:Health News:Genesis Pharmaceuticals Files Counter Claims 2Health News:National Autism Conference to be Held in Weston, FL November 13-16 2Health News:Wolters Kluwer Appoints Robert Becker as President and CEO Wolters Kluwer Health; and Stacey Caywood as President and CEO Wolters Kluwer Law & Business (U.S.) 2Health News:Wolters Kluwer Appoints Robert Becker as President and CEO Wolters Kluwer Health; and Stacey Caywood as President and CEO Wolters Kluwer Law & Business (U.S.) 3Health News:Wolters Kluwer Appoints Robert Becker as President and CEO Wolters Kluwer Health; and Stacey Caywood as President and CEO Wolters Kluwer Law & Business (U.S.) 4Health News:SCOLR Pharma, Inc. Schedules Third Quarter 2008 Financial Results Conference Call for November 7, 2008 at 11:30 A.M. Eastern 2
The IgA in vitro diagnostic enzyme immunoassay is intended for the qualitative detection of anti-human tTG IgA antibodies in human serum as an aid in the diagnosis of CD....
...
... The FIDIS system and its ... simultaneously and on the same sample, ... dedicated to all types of laboratories ... than today their daily routine, as ...
The PICO50 is used for arterial line sampling....
Medicine Products: